HLS Therapeutics (TSE:HLS) Price Target Raised to C$4.00 at Stifel Nicolaus

HLS Therapeutics (TSE:HLS) had its price target upped by Stifel Nicolaus from C$3.50 to C$4.00 in a report issued on Wednesday,BayStreet.CA reports. Stifel Nicolaus currently has a hold rating on the stock.

HLS Therapeutics Price Performance

HLS Therapeutics stock opened at C$4.42 on Wednesday. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01. The stock has a market cap of C$98.33 million, a price-to-earnings ratio of -4.43 and a beta of 1.07. The firm has a 50-day moving average of C$4.17 and a two-hundred day moving average of C$3.80. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.